Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Deininger

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|February 8, 2002
[Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases]Michael Deininger, Dietger Niederwieser
The Lancet. Haematology|January 29, 2021
Eradicating residual chronic myeloid leukaemia: basic research lost in translationHelong Zhao, Michael Deininger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid LeukemiaJavid J Moslehi, Michael Deininger
Blood|March 22, 2023
Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditionsHelong Gary Zhao, Michael Deininger
Leukemia & Lymphoma|October 28, 2020
Imatinib, cheese and migrainesMichael Woodfin, Laura Bickel, Michael Deininger
Current Treatment Options in Oncology|June 10, 2023
Proposals for Clinical Trials in Chronic Myelomonocytic LeukemiaAlexandra Rezazadeh, Michael Deininger, Ehab Atallah
Blood|December 25, 2004
The development of imatinib as a therapeutic agent for chronic myeloid leukemiaMichael Deininger, Elisabeth Buchdunger, Brian J Druker
Haematologica|January 16, 2014
Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesElias Jabbour, Oliver G Ottmann, Michael Deininger, et al.
Design Studies|February 6, 2018
Novice designers' use of prototypes in engineering designMichael Deininger, Shanna R Daly, Kathleen H Sienko, et al.
Leukemia|August 4, 2024
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph<sup>+</sup> leukemias?Nataly Cruz-Rodriguez, Hua Tang, Benjamin Bateman, et al.
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
Medizinische Klinik (Munich, Germany : 1983)|February 8, 2002
[Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases]Michael Deininger, Dietger Niederwieser
The Lancet. Haematology|January 29, 2021
Eradicating residual chronic myeloid leukaemia: basic research lost in translationHelong Zhao, Michael Deininger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid LeukemiaJavid J Moslehi, Michael Deininger
Blood|March 22, 2023
Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditionsHelong Gary Zhao, Michael Deininger
Leukemia & Lymphoma|October 28, 2020
Imatinib, cheese and migrainesMichael Woodfin, Laura Bickel, Michael Deininger
Current Treatment Options in Oncology|June 10, 2023
Proposals for Clinical Trials in Chronic Myelomonocytic LeukemiaAlexandra Rezazadeh, Michael Deininger, Ehab Atallah
Blood|December 25, 2004
The development of imatinib as a therapeutic agent for chronic myeloid leukemiaMichael Deininger, Elisabeth Buchdunger, Brian J Druker
Haematologica|January 16, 2014
Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesElias Jabbour, Oliver G Ottmann, Michael Deininger, et al.
Design Studies|February 6, 2018
Novice designers' use of prototypes in engineering designMichael Deininger, Shanna R Daly, Kathleen H Sienko, et al.
Leukemia|August 4, 2024
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph<sup>+</sup> leukemias?Nataly Cruz-Rodriguez, Hua Tang, Benjamin Bateman, et al.
Pageof 8